Seroquel vs Abilify

Seroquel (quetiapine) consistently causes more significant weight gain than Abilify in clinical comparisons. Studies show Seroquel is associated with average weight gain of 2–4kg over 6–12 weeks, alongside increases in blood glucose and triglycerides. Abilify tends to have a more metabolically neutral profile, though weight gain still occurs in some patients. If metabolic risk is a concern, this distinction is clinically significant and worth discussing with your prescriber.

The FDA added a warning to Abilify in 2016 after receiving reports of patients experiencing uncontrollable urges — including pathological gambling, binge eating, compulsive shopping, and hypersexuality — that they did not have before starting the drug. In many cases, these behaviors stopped when Abilify was discontinued or the dose was lowered. This side effect appears to result from Abilify's dopamine partial agonist activity. Seroquel does not carry this specific warning.

Using two antipsychotics simultaneously is generally not recommended as a first-line approach, but some psychiatrists use combinations for treatment-resistant cases. The combination increases sedation risk, metabolic burden, and the risk of cardiac QT prolongation. If a combination is being considered, it should involve a psychiatrist who has carefully weighed the risk-benefit ratio and is monitoring for additive side effects.